Search results
Showing 241 to 255 of 676 results for diabetes
Evidence-based recommendations on icosapent ethyl (Vazkepa) with statin therapy for reducing the risk of cardiovascular events in adults with raised triglycerides.
Weight management: referral to weight management programmes for obesity (IND220)
This indicator covers the percentage of patients with a BMI of 27.5 kg/m2 or more (or 30 kg/m2 or more if ethnicity is recorded as White) in the preceding 12 months who have been offered referral to a weight management programme within 90 days of the BMI being recorded. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM202
Weight management: advice for people living with overweight (18 to 39 years) (IND319)
This indicator covers the percentage of patients aged 18 to 39 years with a BMI of 23 kg/m2 to 27.4 kg/m2 (or 25 kg/m2 to 29.9 kg/m2 if ethnicity is recorded as White) in the preceding 12 months who have been given weight management advice within 90 days of the BMI being recorded. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
and the impact on mortality, morbidity and limb amputation in people with diabetes? Any explanatory notes(if applicable) Limited...
Bipolar, schizophrenia and other psychoses: annual BMI recording (IND83)
This indicator covers the percentage of patients with schizophrenia, bipolar affective disorder and other psychoses who have a record of BMI in the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomesThis indicator covers the percentage of patients with diabetes with a record of a foot examination and risk classification: 1) low risk (normal sensation, palpable pulses), 2) increased risk (neuropathy or absent pulses), 3) high risk (neuropathy or absent pulses plus deformity or skin changes or previous ulcer) or 4) ulcerated foot within the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM16
Recommendation ID NG3/6 Question In women with type 1 diabetes who are planning to become pregnant, what is the most effective method of
clinical and cost effectiveness of SGLT2 inhibitors in adults with type 2 diabetes, chronic kidney disease and a urine ACR of less than...
Evidence-based recommendations on semaglutide (Wegovy) for managing overweight and obesity in adults.
This guideline covers encouraging people to increase the amount they walk or cycle for travel or recreation purposes.
This indicator covers those patients aged between 25 and 84 years, with a new diagnosis of hypertension or type 2 diabetes recorded in the preceding 12 months (excluding those with pre-existing cardiovascular disease, chronic kidney disease, familial hypercholesterolaemia or type 1 diabetes), who have a recorded cardiovascular risk assessment score of 10% or more in the preceding 12 months: the percentage who are currently treated with a lipid lowering therapy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
multidisciplinary foot care service:- When and with what criteria should people with diabetes be referred to the foot protection service...
Diabetes: statins for primary prevention of CVD (40 years and over)
This guidance has been updated and replaced by NICE indicator 275.
Diabetes: statins for primary prevention of CVD (T2DM and 10% risk)
This guidance has been updated and replaced by NICE indicator 274.
This guideline covers assessing and managing suspected or confirmed cirrhosis in people who are 16 years or older. It aims to improve how cirrhosis is identified and diagnosed, and gives advice on the monitoring, prevention and early management of complications.